Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma

NCT01526135 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT01526135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01526135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Completed
Start date
April 16, 2012
Completion date
July 16, 2021
Enrollment
493 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma (ductal adenocarcinoma)